~~<i id='53B09A9543'><strike id='53B09A9543'><tt id='53B09A9543'><pre id='53B09A9543'></pre></tt></strike></i>~~

Home» comprehensive» focus

focus

author：fashion 2025-09-27 17:59:23 Page View：2

Hiram Secrist (left), who has Duchenne muscular dystrophy, with his mother, Kristen Secrist (center), and his grandmother, Terrie Jordan. Courtesy Secrist family

In mid-July, Kristen Secrist hopped on a call with her 5-year-old son’s doctor, who had urgent news: The first gene therapy had been approved for Duchenne muscular dystrophy. Her son, Hiram, would be a perfect candidate — if, she added, they could get him dosed in time.

The treatment was approved only for 4- and 5-year-olds. Hiram turned 6 in three weeks.

“Oh, crap,” Secrist said to herself.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Buoyed by wins on obesity, Novo Nordisk eyes heart disease
Next article： Activists slam private health insurers over coverage restrictions

leisure time

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

1:19Ademonstratorrunsonthethirdnightofprotestssparkedbythefatalpoliceshootingofa17-year-olddriverint

App could help diagnose ear infections more accurately — and at home

AUWSchoolofMedicineprofessorpracticesusingtheappandfunneltocheckhisdaughter'sear.DennisWise/Universi

Medical leaders decry Supreme Court decision on affirmative action

STEFANIREYNOLDS/AFPviaGettyImagesMedicalleadersonThursdayreactedswiftlytotheSupremeCourt’sdecisionto

Stop the failed accountable care organization experiment

AdobeForthelasthalf-century,Congresshasendorsedessentiallythesameapproachtocuttinghealthcarecosts,an

WSS

focus

focus

explore

leisure time

Stop the failed accountable care organization experiment